Genetic Determinants of Arterial Calcification Associated with Atherosclerosis

Mayo Clinic Proceedings

Volumn 79, Issue 2, 2004, Pages 197-210

  Doherty, Terence M ^a   Fitzpatrick, Lorraine A ^b   Shaheen, Aisha ^c   Rajavashisth, Tripathi B ^a   Detrano, Robert C ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Mayo Clinic   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; ARGININE CARBOXYPEPTIDASE; BONE MORPHOGENETIC PROTEIN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTROGEN RECEPTOR ALPHA; INORGANIC PYROPHOSPHATASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCALCIN; OSTEOPROTEGERIN; PHOSPHODIESTERASE I; STROMELYSIN;

ARTERY CALCIFICATION; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; GENE MAPPING; GENE MUTATION; GENETIC LINKAGE; HUMAN; NONHUMAN; PATHOGENESIS; PHENOTYPE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE;

EID: 0942276273     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/79.2.197     Document Type: Review

References (239)

1. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Dallas, Tex: American Heart Association; 2003. Available at: www.americanheart.org/downloadable/heart /1072969766940HSStats2004Update.pdf. Accessibility verified January 13, 2004.
2. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project: registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90: 583-612.
3. World Health Organization. The World Health Report 1999: Making a Difference. Geneva, Switzerland: World Health Organization; 1999.
4. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-1504.
5. Detrano RC, Doherty TM, Davies MJ, Stary HC. Predicting coronary events with coronary calcium: pathophysiologic and clinical problems. Curr Probl Cardiol. 2000;25:374-402.
6. Doherty TM, Detrano RC, Mautner SL, Mautner GC, Shavelle RM. Coronary calcium: the good, the bad, and the uncertain. Am Heart J. 1999;137:806-814.
7. O'Rourke RA, Brundage BH, Froelicher VF, et al. American College of Cardiology/American Heart Association expert consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol. 2000;36:326-340.
8. O'Malley PG, Taylor AJ, Jackson JL, Doherty TM, Detrano RC. Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. Am J Cardiol. 2000;85:945-948.
9. Sangiorgi G, Rumberger JA, Severson A, et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol. 1998;31:126-133.
10. Stary HC. Natural history of calcium deposits in atherosclerosis progression and regression. Z Kardiol. 2000;89(suppl 2):28-35.
11. Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: intima versus media. Herz. 2001;26:245-251.
12. Doherty TM, Fitzpatrick LA, Inoue D, et al. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endocr Rev. In press.
13. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(12, suppl):S16-S23.
14. Schoenhagen P, Tuzcu EM. Coronary artery calcification and end-stage renal disease: vascular biology and clinical implications. Cleve Clin J Med. 2002;69(suppl 3):S12-S20.
15. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-1483.
16. Moe SM, O'Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 2002;61:638-647.
17. Edmonds ME. Medial arterial calcification and diabetes mellitus. Z Kardiol. 2000;89(suppl 2):101-104.
18. Goebel FD, Fuessl HS. Mönckeberg's sclerosis after sympathetic denervation in diabetic and non-diabetic subjects. Diabetologia. 1983;24:347-350.
19. Young MJ, Adams JE, Anderson GF, Boulton AJ, Cavanagh PR. Medial arterial calcification in the feet of diabetic patients and matched non-diabetic control subjects. Diabetologia. 1993;36;615-621.
20. Gilbey SG, Walters H, Edmonds ME, et al. Vascular calcification, autonomic neuropathy, and peripheral blood flow in patients with diabetic nephropathy. Diabet Med. 1989;6:37-42.
21. Lillioja S, Nyomba BL, Saad MF, et al. Exaggerated early insulin release and insulin resistance in a diabetes-prone population: a metabolic comparison of Pima Indians and Caucasians. J Clin Endocrinol Metab. 1991;73:866-876.
22. Howard BV, Lee ET, Cowan LD, et al. Coronary heart disease prevalence and its relation to risk factors in American Indians: the Strong Heart Study. Am J Epidemiol. 1995;142:254-268.
23. Narayan KM, Pettitt DJ, Hanson RL, et al. Familial aggregation of medial arterial calcification in Pima Indians with and without diabetes. Diabetes Care. 1996;19:968-971.
24. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M. Medial artery calcification: a neglected harbinger of cardiovascular complications in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996;16:978-983.
25. Niskanen L, Siitonen O, Suhonen M, Uusitupa MI. Medial artery calcification predicts cardiovascular mortality in patients with NIDDM. Diabetes Care. 1994;17:1252-1256.
26. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT. Diffuse calcification in human coronary arteries: association of osteopontin with atherosclerosis. J Clin Invest. 1994;94:1597-1604.
27. Parhami F, Tintut Y, Patel JK, Mody N, Hemmat A, Demer LL. Regulation of vascular calcification in atherosclerosis. Z Kardiol. 2001;90(suppl 3):27-30.
28. Bostrom K, Demer LL. Regulatory mechanisms in vascular calcification. Crit Rev Eukaryot Gene Expr. 2000;10:151-158.
29. Doherty TM, Uzui H, Fitzpatrick LA, et al. Rationale for the role of osteoclast-like cells in arterial calcification. FASEB J. 2002;16:577-582.
30. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.
31. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503-516.
32. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
33. Libby P. The vascular biology of atherosclerosis. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease: A Textbook of Cardiovascular Medicine. Vol 1. 6th ed. Philadelphia, Pa: WB Saunders Co; 2001:995-1009.
34. Moraghan T, Antoniucci DM, Grenert JP, et al. Differential response in cell proliferation to beta estradiol in coronary arterial vascular smooth muscle cells obtained from mature female versus male animals. Endocrinology. 1996;137:5174-5177.
35. Severson AR, Ingram RT, Fitzpatrick LA. Matrix proteins associated with bone calcification are present in human vascular smooth muscle cells grown in vitro. In Vitro Cell Dev Biol Anim. 1995;31: 853-857.
36. Fitzpatrick LA, Turner RT, Ritman ER. Endochondral bone formation in the heart: a possible mechanism of coronary calcification. Endocrinology. 2003;144:2214-2219.
37. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1998-2003.
38. Sheth SS, Deluna A, Allayee H, Lusis AJ. Understanding atherosclerosis through mouse genetics. Curr Opin Lipidol. 2002;13:181-189.
39. Wang X, Paigen B. Comparative genetics of atherosclerosis and restenosis: exploration with mouse models [editiorial]. Arterioscler Thromb Vasc Biol. 2002;22:884-886.
40. Knowles JW, Maeda N. Genetic modifiers of atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2000;20:2336-2345.
41. Andreotti F, Porto I, Crea F, Maseri A. Inflammatory gene polymorphisms and ischaemic heart disease: review of populaticn association studies. Heart. 2002;87:107-112.
42. Lopes N, Vasudevan SS, Alvarez RJ, Binkley PF, Goldschmidt PJ. Pathophysiology of plaque instability: insights at the genomic level. Prog Cardiovasc Dis. 2002;44:323-338.
43. von Kodolitsch Y, Pyeritz RE, Rogan PK. Splice-site mutations in atherosclerosis candidate genes: relating individual information to phenotype [published correction appears in Circulation. 1999; 100:2205]. Circulation. 1999;100:693-699.
44. von Kodolitsch Y, Pyeritz RE, Rogan PK. Splice-site mutations in atherosclerosis candidate genes: relating individual information to phenotype [published correction appears in Circulation. 1999; 100:2205]. Circulation. 1999;100:693-699.
45. Peyser PA. Genetic epidemiology of coronary artery disease. Epidemiol Rev. 1997;19:80-90.
46. Strong JP, Malcom GT, Oalmann MC. Environmental and genetic risk factors in early human atherogenesis: lessons from the PDAY study. Pathol Int. 1995;45:403-408.
47. Neufeld HN, Goldbourt U. Coronary heart disease: genetic aspects. Circulation. 1983;67:943-954.
48. Canfield AE, Farrington C, Dziobon MD, et al. The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study. J Pathol. 2002;196:228-234.
49. Christian RC, Harrington S, Edwards WD, Oberg AL, Fitzpatrick LA. Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women. J Clin Endocrinol Metab. 2002;87:1062-1067.
50. Zebboudj AF, Imura M, Boström K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem. 2002;277:4388-4394.
51. Gijsbers BL, van Haarlem LJ, Soute BA, Ebberink RH, Vermeer C. Characterization of a Gla-containing protein from calcified human atherosclerotic plaques. Arteriosclerosis. 1990;10:991-995.
52. Doherty TM, Detrano RC. Coronary arterial calcification as an active process: a new perspective on an old problem. Calcif Tissue Int. 1994;54:224-230.
53. Schurgers LJ, Dissel PE, Spronk HM, et al. Role of vitamin K and vitamin K-dependent proteins in vascular calcification. Z Kardiol. 2001;90(suppl 3):57-63.
54. Schinke T, Karsenty G. Vascular calcification - a passive process in need of inhibitors [editorial]. Nephrol Dial Transplant. 2000; 15:1272-1274.
55. Schinke T, McKee MD, Karsenty G. Extracellular matrix calcification: where is the action? Nat Genet. 1999;21:150-151.
56. Wallin R, Cain D, Sane DC. Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells - a cell system which resembles the system in bone cells. Thromb Haemost. 1999;82:1764-1767.
57. Shanahan CM, Proudfoot D, Farzaneh-Far A, Weissberg PL. The role of Gla proteins in vascular calcification. Crit Rev Eukaryct Gene Expr. 1998;8:357-375.
58. Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev. 1989;69:990-1047.
59. Price PA. Gla-containing proteins of bone. Connect Tissue Rev. 1989;21:51-57.
60. Price PA. Role of vitamin-K-dependent proteins in bone metabolism. Annu Rev Nutr. 1988;8:565-583.
61. Price PA, Williamson MK. Primary structure of bovine matrix Gla protein, a new vitamin K-dependent bone protein. J Biol Chem. 1985;260:14971-14975.
62. Lian JB, Gundberg CM. Osteocalcin: biochemical considerations and clinical applications. Clin Orthop. 1988;226:267-291.
63. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78-81.
64. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001;21:1610-1616.
65. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001;21:817-824.
66. Price PA, Faus SA, Williamson MK. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol. 2000;20:317-327.
67. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol. 1998;18:1400-1407.
68. Matsui Y, Rittling SR, Okamoto H, et al. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1029-1034.
69. Ducy P, Schinke T, Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science. 2000;289:1501-1504.
70. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000; 289:1504-1508.
71. Minisola S, Fitzpatrick LA. Bone physiology. In: Eugster EA, Pescovitz OH, eds. Developmental Endocrinology: From Research to Clinical Practice. Totowa, NJ: Humana Press; 2002: 193-216.
72. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome [published correction appears in Science. 2001;292:1838]. Science. 2001;291:1304-1351.
73. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome [published correction appears in Science. 2001;292:1838]. Science. 2001;291:1304-1351.
74. Wang Z, Moult J. SNPs, protein structure, and disease. Hum Mutat. 2001;17:263-270.
75. Taillon-Miller P, Gu Z, Li Q, Hillier L, Kwok PY. Overlapping genomic sequences: a treasure trove of single-nucleotide polymorphisms. Genome Res. 1998;8:748-754.
76. Collins FS, Brooks LD, Chakravarti A. A DNA polymorphism discovery resource for research on human genetic variation [published correction appears in Genome Res. 1999;9:210]. Genome Res. 1998;8:1229-1231.
77. Collins FS, Brooks LD, Chakravarti A. A DNA polymorphism discovery resource for research on human genetic variation [published correction appears in Genome Res. 1999;9:210]. Genome Res. 1998;8:1229-1231.
78. Tefferi A, Wieben ED, Dewald GW, Whiteman DAH, Bernard ME, Spelsberg TC. Primer on medical genomics, part II: background principles and methods in molecular genetics. Mayo Clin Proc. 2002;77:785-808.
79. Collins FS, Guyer MS, Charkravarti A. Variations on a theme: cataloging human DNA sequence variation. Science. 1997;278: 1580-1581.
80. Cargill M, Altshuler D, Ireland J, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes [published correction appears in Nat Genet. 1999;23:373]. Nat Genet. 1999;22:231-238.
81. Cargill M, Altshuler D, Ireland J, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes [published correction appears in Nat Genet. 1999;23:373]. Nat Genet. 1999;22:231-238.
82. Halushka MK, Fan JB, Bentley K, et al. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet. 1999;22:239-247.
83. Krawczak M, Ball EV, Fenton I, et al. Human gene mutation database - a biomedical information and research resource. Hum Mutat. 2000;15:45-51.
84. Morgan TH. Chromosomes and heredity. Am Nat. 1910;44:449-496.
85. Morgan TH. Sex-limited inheritance in Drosophila. Science. 1910;32:120-122.
86. Luo ZW, Wu CI. Modeling linkage disequilibrium between a polymorphic marker locus and a locus affecting complex dichotomous traits in natural populations. Genetics. 2001;158:1785-1800.
87. Rice JP, Saccone NL, Corbett J. The lod score method. Adv Genet. 2001;42:99-113.
88. Elston RC. Linkage and association. Genet Epidemiol. 1998;15: 565-576.
89. Mautner GC, Mautner SL, Froehlich J, et al. Coronary artery calcification: assessment with electron beam CT and histomorphometric correlation. Radiology. 1994;192:619-623.
90. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area: a histopathologic correlative study. Circulation. 1995;92:2157-2162.
91. Mintz GS, Pichard AD, Popma JJ, et al. Determinants and correlates of target lesion calcium in coronary artery disease: a clinical, angiographic and intravascular ultrasound study. J Am Coll Cardiol. 1997;29:268-274.
92. Maehara A, Fitzgerald PJ. Coronary calcification: assessment by intravascular ultrasound imaging. Z Kardiol. 2000;89(suppl 2):112-116.
93. Newman AB, Naydeck BL, Sutton-Tyrrell K, Feldman A, Edmundowicz D, Kuller LH. Coronary artery calcification in older adults to age 99: prevalence and risk factors. Circulation. 2001;104:2679-2684.
94. Bild DE, Folsom AR, Lowe LP, et al. Prevalence and correlates of coronary calcification in black and white young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Arterioscler Thromb Vasc Biol. 2001;21:852-857.
95. Wong ND, Kouwabunpat D, Vo AN, et al. Coronary calcium and atherosclerosis by ultrafast computed tomography in asymptomatic men and women: relation to age and risk factors. Am Heart J. 1994;127:422-430.
96. Mahoney LT, Burns TL, Stanford W, et al. Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: The Muscatine Study. J Am Coll Cardiol. 1996;27:277-284.
97. Maher JE, Raz JA, Bielak LF, Sheedy PF II, Schwartz RS, Peyser PA. Potential of quantity of coronary artery calcification to identify new risk factors for asymptomatic atherosclerosis. Am J Epidemiol. 1996;144:943-953.
98. Valdes AM, Wolfe ML, Tate HC, Gefter W, Rut A, Rader DJ. Association of traditional risk factors with coronary calcification in persons with a family history of premature coronary heart disease: the study of the inherited risk of coronary atherosclerosis. J Investig Med. 2001;49:353-361.
99. Detrano RC, Wong ND, French WJ, et al. Prevalence of fluoroscopic coronary calcific deposits in high-risk asymptomatic persons. Am Heart J. 1994;127:1526-1532.
100. Teng W, Wong ND, Abrahamson D, Gardin JM. Relation of electron beam computed tomography screening for coronary calcium to cardiovascular risk and disease: a review. Coron Artery Dis. 1996;7:383-389.
101. Peyser PA, Bielak LF, Chu JS, et al. Heritability of coronary artery calcium quantity measured by electron beam computed tomography in asymptomatic adults. Circulation. 2002;106:304-308.
102. O'Donnell CJ, Chazaro I, Wilson PW, et al. Evidence for heritability of abdominal aortic calcific deposits in the Framingham Heart Study. Circulation. 2002;106:337-341.
103. Lange LA, Lange EM, Bielak LF, et al. Autosomal genome-wide scan for coronary artery calcification loci in sibships at high risk for hypertension. Arterioscler Thromb Vasc Biol. 2002;22:418-423.
104. Newman AB, Naydeck BL, Whittle J, Sutton-Tyrrell K, Edmundowicz D, Kuller LH. Racial differences in coronary artery calcification in older adults. Arterioscler Thromb Vasc Biol. 2002;22:424-430.
105. Doherty TM, Tang W, Detrano RC. Racial differences in the sigmficance of coronary calcium in asymptomatic black and white subjects with coronary risk factors. J Am Coll Cardiol. 1999;34: 787-794.
106. Tang W, Detrano RC, Brezden OS, et al. Racial differences in coronary calcium prevalence among high-risk adults. Am J Cardiol. 1995;75:1088-1091.
107. Tejada C, Strong JP, Montenegro MR, Restrepo C, Solberg LA. Distribution of coronary and aortic atherosclerosis by geographic location, race, and sex. Lab Invest. 1968;18:509-526.
108. Strong JP, McGill HC Jr. The natural history of coronary atherosclerosis. Am J Pathol. 1962;40:37-49.
109. Strong JP, McGill HC Jr. The natural history of aortic atherosclerosis: relationship to race, sex, and coronary lesions in New Orleans. Exp Mol Pathol. 1963;52(suppl 1):15-27.
110. D'Agostino RB Jr, Burke G, O'Leary D, et al. Ethnic differences in carotid wall thickness: the Insulin Resistance Atherosclerosis Study. Stroke. 1996;27:1744-1749.
111. Sacco RL, Roberts JK, Boden-Albala B, et al. Race-ethnicity and determinants of carotid atherosclerosis in a multiethnic population: the Northern Manhattan Stroke Study. Stroke. 1997;28:929-935.
112. McGarry P, Solberg LA, Guzman MA, Strong JP. Cerebral atherosclerosis in New Orleans: comparisons of lesions by age, sex, and race. Lab Invest. 1985;52:533-539.
113. Brasier AR, Recinos A III, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002;22:1257-1266.
114. Lonn E. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Curr Atheroscler Rep. 2002;4:363-372.
115. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol. 2002;89(2A):18A-25A.
116. Wang JG, Staessen JA. Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease. Eur J Pharmacol. 2000;410:289-302.
117. Bauters C, Amouyel P. Association between the ACE genotype and coronary artery disease: insights from studies on restenosis, vasomotion and thrombosis. Eur Heart J. 1998;19(suppl J):J24-J29.
118. Cambien F, Evans A. Angiotensin I converting enzyme gene polymorphism and coronary heart disease. Eur Heart J. 1995; 16(suppl K):13-22.
119. Bauters C, Amouyel P, Bertrand ME. ACE gene polymorphism and coronary restenosis. Semin Interv Cardiol. 1999;4:145-149.
120. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
121. Wang XL, McCredie RM, Wilcken DE. Genotype distribution of angiotensin-converting enzyme polymorphism in Australian healthy and coronary populations and relevance to myocardial infarction and coronary artery disease. Arterioscler Thromb Vasc Biol. 1996;16:115-119.
122. Ludwig E, Corneli PS, Anderson JL, Marshall HW, Lalouel JM, Ward RH. Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis. Circulation. 1995;91:2120-2124.
123. Arbustini E, Grasso M, Fasani R, et al. Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. Br Heart J. 1995;74:584-591.
124. Nakai K, Itoh C, Miura Y, et al. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese. Circulation. 1994;90:2199-2202.
125. Ruiz J, Blanche H, Cohen N, et al. Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A. 1994;91:3662-3665.
126. Mattu RK, Needham EW, Galton DJ, Frangos E, Clark AJ, Caulfield M. A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study. Circulation. 1995;91:270-274.
127. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med. 1995;332:706-711.
128. Friedl W, Krempler F, Paulweber B, Pichler M, Sandhofer F. A deletion polymorphism in the angiotensin converting enzyme gene is not associated with coronary heart disease in an Austrian population. Atherosclerosis. 1995;112:137-143.
129. Pfohl M, Athanasiadis A, Koch M, et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound. J Am Coll Cardiol. 1998;31:987-991.
130. Brown MS, Goldstein JL. Lipoprotein receptors in the liver: control signals for plasma cholesterol traffic. J Clin Invest. 1983;72: 743-747.
131. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 1983;52:223-261.
132. Strittmatter WJ, Bova Hill C. Molecular biology of apolipoprotein E. Curr Opin Lipidol. 2002;13:119-123.
133. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002;155:487-495.
134. de Knijff P, Havekes LM. Apolipoprotein E as a risk factor for coronary heart disease: a genetic and molecular biology approach. Curr Opin Lipidol. 1996;7:59-63.
135. Contois JH, Anamani DE, Tsongalis GJ. The underlying molecular mechanism of apolipoprotein E polymorphism: relationships to lipid disorders, cardiovascular disease, and Alzheimer's disease. Clin Lab Med. 1996;16:105-123.
136. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988;8:1-21.
137. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: the Framingham Offspring Study. JAMA. 1994;272: 1666-1671.
138. Stengard JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation. 1995;91:265-269.
139. van Bockxmeer FM, Mamotte CD. Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet. 1992;340:879-880.
140. Kuusi T, Nieminen MS, Ehnholm C, et al. Apoprotein E polymorphism and coronary artery disease: increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients. Arteriosclerosis. 1989;9:237-241.
141. Gerdes LU, Klausen IC, Sihm I, Faergeman O. Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world. Genet Epidemiol. 1992;9:155-167.
142. Kardia SL, Haviland MB, Ferrell RE, Sing CF. The relationship between risk factor levels and presence of coronary artery calcification is dependent on apolipoprotein E genotype. Arterioscler Thromb Vasc Biol. 1999;19:427-435.
143. Prescott SM, McIntyre TM, Zimmerman GA, Stafforini DM. Sol Sherry lecture in thrombosis: molecular events in acute inflammation. Arterioscler Thromb Vasc Biol. 2002;22:727-733.
144. Krieglstein CF, Granger DN. Adhesion molecules and their role in vascular disease. Am J Hypertens. 2001;14(6, pt 2):44S-54S.
145. Hartwell DW, Wagner DD. New discoveries with mice mutant in endothelial and platelet selectins. Thromb Haemost. 1999;82:850-857.
146. Yoshida M, Gimbrone MA Jr. Novel roles for E-selectin in endothelial-leukocyte adhesion. Ann N Y Acad Sci. 1997;811:493-497.
147. Dimitroff CJ, Lee JY, Rafii S, Fuhlbrigge RC, Sackstein R. CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol. 2001;153:1277-1286.
148. Wild MK, Huang MC, Schulze-Horsel U, van der Merwe PA, Vestweber D. Affinity, kinetics, and thermodynamics of E-selectin binding to E-selectin ligand-1. J Biol Chem. 2001;276:31602-31612.
149. Frenette PS, Subbarao S, Mazo IB, von Andrian UH, Wagner DD. Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow. Proc Natl Acad Sci U S A. 1998;95:14423-14428.
150. Mazo IB, Gutierrez-Ramos JC, Frenette PS, Hynes RO, Wagner DD, von Andrian UH. Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1 [published correction appears in J Exp Med. 1998;188:1001]. J Exp Med. 1998;188: 465-474.
151. Mazo IB, Gutierrez-Ramos JC, Frenette PS, Hynes RO, Wagner DD, von Andrian UH. Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1 [published correction appears in J Exp Med. 1998;188:1001]. J Exp Med. 1998;188: 465-474.
152. Schweitzer KM, Drager AM, van der Valk P, et al. Constitutive expression of E-selectin and vascular cell adhesion molecule-1 on endothelial cells of hematopoietic tissues. Am J Pathol. 1996;148: 165-175.
153. Shalhoub V, Elliott G, Chiu L, et al. Characterization of osteoclast precursors in human blood. Br J Haematol. 2000;111:501-512.
154. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA. The human osteoclast precursor circulates in the monocyte fraction. Endocrinology. 1996;137:4058-4060.
155. Fujikawa Y, Sabokbar A, Neale SD, Itonaga I, Torisu T, Athanasou NA. The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3,-6, and -11, tumor necrosis factor-α, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells. Bone. 2001;28:261-267.
156. Wenzel K, Hanke R, Speer A. Polymorphism in the human E-selectin gene detected by PCR-SSCP. Hum Genet. 1994;94:452-453.
157. Revelle BM, Scott D, Beck PJ. Single amino acid residues in the E- and P-selectin epidermal growth factor domains can determine carbohydrate binding specificity. J Biol Chem. 1996;271:16160-16170.
158. Wenzel K, Blackburn A, Ernst M, et al. Relationship of polymorphisms in the renin-angiotensin system and in E-selectin of patients with early severe coronary heart disease. J Mol Med. 1997; 75:57-61.
159. Wenzel K, Felix S, Kleber FX, et al. E-selectin polymorphism and atherosclerosis: an association study. Hum Mol Genet. 1994;3: 1935-1937.
160. Ellsworth DL, Bielak LF, Turner ST, Sheedy PF II, Boerwinkle E, Peyser PA. Gender- and age-dependent relationships between the E-selectin S128R polymorphism and coronary artery calcification. J Mol Med. 2001;79:390-398.
161. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801-1811.
162. Koh KK, Cardillo C, Bui MN, et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation. 1999;99:354-360.
163. Shah PK, Wilkin DJ, Doherty TM, et al. Therapeutic developments in matrix metalloproteinase inhibition. Expert Opin Ther Patents. 2002;12:665-707.
164. Hayakawa T. Multiple functions of tissue inhibitors of metalloproteinases (TIMPs): a new aspect involving osteoclastic bone resorption. J Bone Miner Metab. 2002;20:1-13.
165. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111-122.
166. Shah PK, Galis ZS. Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain [editorial]. Circulation. 2001;104:1878-1880.
167. Bord S, Horner A, Hembry RM, Reynolds JJ, Compston JE. Distribution of matrix metalloproteinases and their inhibitor, TIMP-1, in developing human osteophytic bone. J Anat. 1997; 191(pt 1):39-48.
168. Kawashima-Ohya Y, Satakeda H, Kuruta Y, et al. Effects of parathyroid hormone (PTH) and PTH-related peptide on expressions of matrix metalloproteinase-2, -3, and -9 in growth plate chondrocyte cultures. Endocrinology. 1998;139:2120-2127.
169. Bord S, Horner A, Hembry RM, Compston JE. Stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10) expression in developing human bone: potential roles in skeletal development. Bone. 1998;23:7-12.
170. Dew G, Murphy G, Stanton H, et al. Localisation of matrix metalloproteinases and TIMP-2 in resorbing mouse bone. Cell Tissue Res. 2000;299:385-394.
171. Uchida M, Shima M, Shimoaka T, et al. Regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) by bone resorptive factors in osteoblastic cells. J Cell Physiol. 2000;185:207-214.
172. Kusano K, Miyaura C, Inada M, et al. Regulation of matrix metalloproteinases (MMP-2,-3,-9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology. 1998;139:1338-1345.
173. Yabe H, Fukuma M, Urano F, et al. Lack of matrix metalloproteinase (MMP)-1 and -3 expression in Ewing sarcoma may be due to loss of accessibility of the MMP regulatory element to the specific fusion protein in vivo. Biochem Biophys Res Commun. 2002;293:61-71.
174. Ramamurthy NS, Xu JW, Bird J, et al. Inhibition of alveolar bone loss by matrix metalloproteinase inhibitors in experimental periodontal disease. J Periodontal Res. 2002;37:1-7.
175. Ribbens C, Martin y Porras M, Franchimont N, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis. 2002;61:161-166.
176. Takahashi M, Haro H, Wakabayashi Y, Kawa-uchi T, Komori H, Shinomiya K. The association of degeneration of the intervertebral disc with 5a/6a polymorphism in the promoter of the human matrix metalloproteinase-3 gene. J Bone Joint Surg Br. 2001; 83:491-495.
177. Ribbens C, Andre B, Kaye O, et al. Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not. Rheumatology (Oxford). 2000;39: 1357-1365.
178. Jingushi S, Lohmander LS, Shinmei M, et al. Markers of joint tissue turnover in joint fluids from hips with osteonecrosis of the femoral head. J Orthop Res. 2000;18:728-733.
179. Bini A, Mann KG, Kudryk BJ, Schoen FJ. Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1999;19:1852-1861.
180. Rundek T, Elkind MS, Pittman J, et al. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke. 2002;33:1420-1423.
181. Humphries S, Bauters C, Meirhaeghe A, Luong L, Bertrand M, Amouyel P. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur Heart J. 2002;23:721-725.
182. Kim JS, Park HY, Kwon JH, et al. The roles of stromelysin-1 and the
183. Pollanen P, Lehtimaki T, Ilveskoski E, et al. Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3: the Helsinki Sudden Death Study. Atherosclerosis. 2002;164:329-335.
184. Otawara Y, Price PA. Developmental appearance of matrix GLA protein during calcification in the rat. J Biol Chem. 1986;261: 10828-10832.
185. Spronk HM, Soute BA, Schurgers LJ, et al. Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun. 2001;289:485-490.
186. Hao H, Hirota S, Tsukamoto Y, Imakita M, Ishibashi-Ueda H, Yutani C. Alterations of bone matrix protein mRNA expression in rat aorta in vitro. Arterioscler Thromb Vasc Biol. 1995;15:1474-1480.
187. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL. High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest. 1994;93:2393-2402.
188. Bostrom K, Tsao D, Shen S, Wang Y, Demer LL. Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. J Biol Chem. 2001;276:14044-14052.
189. Wallin R, Cain D, Hutson SM, Sane DC, Loeser R. Modulation of the binding of matrix Gla protein (MGP) to bone morphogenetic protein-2 (BMP-2). Thromb Haemost. 2000;84:1039-1044.
190. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91:1800-1809.
191. Herrmann SM, Whatling C, Brand E, et al. Polymorphisms of the human matrix gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol. 2000;20: 2386-2393.
192. Farzaneh-Far A, Davies JD, Braam LA, et al. A polymorphism of the human matrix gamma-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem. 2001; 276:32466-32473.
193. Tsukamoto K, Orimo H, Hosoi T, et al. Association of bone mineral density with polymorphism of the human matrix Gla protein locus in elderly women. J Bone Miner Metab. 2000;18:27-30.
194. Watanabe I, Tsukamoto K, Shiba T, Emi M. Isolation and radiation hybrid mapping of dinucleotide repeat polymorphism at the human matrix Gla protein (MGP) locus. J Hum Genet. 1998;43: 75-76.
195. Munroe PB, Olgunturk RO, Fryns JP, et al. Mutations in the gene encoding the human matrix Gla protein cause Keutel syndrome. Nat Genet. 1999;21:142-144.
196. Fryns JP, van Fleteren A, Mattelaer P, van den Berghe H. Calcification of cartilages, brachytelephalangy and peripheral pulmonary stenosis: confirmation of the Keutel syndrome. Eur J Pediatr. 1984;142:201-203.
197. Gosling J, Slaymaker S, Gu L, et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999;103:773-778.
198. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894-897.
199. Volejnikova S, Laskari M, Marks SC Jr, Graves DT. Monocyte recruitment and expression of monocyte chemoattractant protein-1 are developmentally regulated in remodeling bone in the mouse. Am J Pathol. 1997;150:1711-1721.
200. Graves DT, Jiang Y, Valente AJ. Regulated expression of MCP-1 by osteoblastic cells in vitro and in vivo. Histol Histopathol. 1999; 14:1347-1354.
201. Takeshita A, Chen Y, Watanabe A, Kitano S, Hanazawa S. TGF-β induces expression of monocyte chemoattractant JE/monocyte chemoattractant protein 1 via transcriptional factor AP-1 induced by protein kinase in osteoblastic cells. J Immunol. 1995;155:419-426.
202. Graves DT, Jiang Y, Valente AJ. The expression of monocyte chemoattractant protein-1 and other chemokines by osteoblasts. Front Biosci. 1999;4:D571-D580.
203. Bost KL, Bento JL, Petty CC, Schrum LW, Hudson MC, Marriott I. Monocyte chemoattractant protein-1 expression by osteoblasts following infection with Staphylococcus aureus or Salmonella. J Interferon Cytokine Res. 2001;21:297-304.
204. Lisignoli G, Toneguzzi S, Pozzi C, et al. Proinflammatory cytokines and chemokine production and expression by human osteoblasts isolated from patients with rheumatoid arthritis and osteoarthritis. J Rheumatol. 1999;26:791-799.
205. Lisignoli G, Toneguzzi S, Pozzi C, et al. Chemokine expression by subchondral bone marrow stromal cells isolated from osteoarthritis (OA) and rheumatoid arthritis (RA) patients. Clin Exp Immunol. 1999;116:371-378.
206. Rahimi P, Wang CY, Stashenko P, Lee SK, Lorenzo JA, Graves DT. Monocyte chemoattractant protein-1 expression and monocyte recruitment in osseous inflammation in the mouse. Endocrinology. 1995;136:2752-2759.
207. Petersen DC, Laten A, Zeier MD, Grimwood A, Rensburg EJ, Hayes VM. Novel mutations and SNPs identified in CCR2 using a new comprehensive denaturing gradient gel electrophoresis assay. Hum Mutat. 2002;20:253-259.
208. Abdi R, Tran TB, Sahagun-Ruiz A, et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol. 2002;13:754-758.
209. Tang J, Shelton B, Makhatadze NJ, et al. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol. 2002;76:662-672.
210. Smith MW, Dean M, Carrington M, et al, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science. 1997;277:959-965.
211. Gonzalez P, Alvarez R, Batalla A, et al. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun. 2001;2:191-195.
212. Valdes AM, Wolfe ML, O'Brien EJ, et al. Va164Ile polymorphism in the C-C chemokine receptor 2 is associated with reduced coronary artery calcification. Arterioscler Thromb Vasc Biol. 2002;22: 1924-1928.
213. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med. 2002;346:340-352.
214. Boukhris R, Becker KL. Calcification of the aorta and osteoporosis: a roentgenographic study. JAMA. 1972;219:1307-1311.
215. Barengolts EI, Berman M, Kukreja SC, Kouznetsova T, Lin C, Chomka EV. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int. 1998; 62:209-213.
216. Ouchi Y, Akishita M, de Souza AC, Nakamura T, Orimo H. Age-related loss of bone mass and aortic/aortic valve calcification-reevaluation of recommended dietary allowance of calcium in the elderly. Ann N Y Acad Sci. 1993;676:297-307.
217. Banks LM, Lees B, Macsweeney JE, Stevenson JC. Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: links between osteoporosis and cardiovascular disease? Eur J Clin Invest. 1994;24:813-817.
218. Laroche M, Pouilles JM, Ribot C, et al. Comparison of the bone mineral content of the lower limbs in men with ischaemic atherosclerotic disease. Clin Rheumatol. 1994;13:611-614.
219. Frye MA, Melton LJ III, Bryant SC, et al. Osteoporosis and calcification of the aorta. Bone Miner. 1992;19:185-194.
220. Lehtimaki T, Kunnas TA, Mattila KM, et al. Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study. J Mol Med. 2002;80:176-180.
221. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man [published correction appears in N Engl J Med. 1995;332:131]. N Engl J Med. 1994;331:1056-1061.
222. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man [published correction appears in N Engl J Med. 1995;332:131]. N Engl J Med. 1994;331:1056-1061.
223. Sudhir K, Chou TM, Chatterjee K, et al. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation. 1997;96:3774-3777.
224. Sudhir K, Chou TM, Messina LM, et al. Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene [letter]. Lancet. 1997;349:1146-1147.
225. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002;22:549-553.
226. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-1268.
227. Cundy T, Hegde M, Naot D, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet. 2002;11:2119-2127.
228. Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002;347:175-184.
229. Galvin KM, Donovan MJ, Lynch CA, et al. A role for Smad6 in development and homeostasis of the cardiovascular system. Nat Genet. 2000;24:171-174.
230. Valdimarsdottir G, Goumans MJ, Rosendahl A, et al. Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation. 2002;106:2263-2270.
231. Johnson K, Goding J, Van Etten D, et al. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res. 2003;18:994-1004.
232. Bollen M, Gijsbers R, Ceulemans H, Stalmans W, Stefan C. Nucleotide pyrophosphatases/phosphodiesterases on the move. Crit Rev Biochem Mol Biol. 2000;35:393-432.
233. Goding JW, Howard MC. Ecto-enzymes of lymphoid cells. Immunol Rev. 1998;161:5-10.
234. Rutsch F, Ruf N, Vaingankar S, et al. Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet. 2003;34:379-381.
235. Yamamoto Y, Furukawa K, Ueyama K, Nakanishi T, Takigawa M, Harata S. Possible roles of CTGF/Hcs24 in the initiation and development of ossification of the posterior longitudinal ligament. Spine. 2002;27:1852-1857.
236. Wang PN, Chen SS, Liu HC, Fuh JL, Kuo BI, Wang SJ. Ossification of the posterior longitudinal ligament of the spine: a case-control risk factor study. Spine. 1999;24:142-144.
237. Furushima K, Shimo-Onoda K, Maeda S, et al. Large-scale screening for candidate genes of ossification of the posterior longitudinal ligament of the spine. J Bone Miner Res. 2002;17:128-137.
238. Rutsch F, Terkeltaub R. Parallels between arterial and cartilage calcification: what understanding artery calcification can teach us about chondrocalcinosis. Curr Opin Rheumatol. 2003;15:302-310.
239. Rutsch F, Vaingankar S, Johnson K, et al. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol. 2001;158:543-554.